Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Nanomedicine Nanotechnology, Biol Med
During your consultation, you should advise us regarding the following medical conditions: Kidney disease or problems with your pancreas Have type 2 diabetes and a history of diabetic retinopathy Are pregnant or plan to become pregnant as weight loss drugs can harm an unborn baby Are breastfeeding or plan to breastfeed Have suffered from depression, suicidal thoughts or mental health issues GLP-1 Agonists MedicationsGLP-1 Agonists Medication slows stomach emptying and can affect other medications, especially those that must pass through the stomach quickly
Supports Energy MetabolismHelps convert fatty acids into energy, aiding both physical and mental performance
Gerstein HC, Colhoun HM, Dagenais GR, et al
In this guide, youll learn about Anthems eligibility criteria, how to check your plans coverage, online prescription options, reasons for possible denials, tips for improving your chances of approval, cost-saving alternatives, and how to request prior authorization
Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record
